Universitat de Lleida
    • English
    • català
    • español
  • English 
    • English
    • català
    • español
  • Login
Repositori Obert UdL
View Item 
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Glial activation and central synapse loss, but not motoneuron degeneration, are prevented by the sigma-1 receptor agonist PRE-084 in the Smn2B/- mouse model of spinal muscular atrophy

Thumbnail
View/Open
Postprint (3.428Mb)
Issue date
2018
Author
Cerveró Cebrià, Clàudia
Blasco Carmona, Alba
Tarabal Mostazo, Olga
Casanovas i Llorens, Anna
Piedrafita Llorens, Lídia
Navarro, Xavier
Esquerda Colell, Josep
Calderó i Pardo, Jordi
Suggested citation
Cerveró Cebrià, Clàudia; Blasco Carmona, Alba; Tarabal Mostazo, Olga; Casanovas i Llorens, Anna; Piedrafita Llorens, Lídia; Navarro, Xavier; ... Calderó i Pardo, Jordi. (2018) . Glial activation and central synapse loss, but not motoneuron degeneration, are prevented by the sigma-1 receptor agonist PRE-084 in the Smn2B/- mouse model of spinal muscular atrophy. Journal of Neuropathology and Experimental Neurology, 2018, vol. 77, num. 7, p. 577-597. https://doi.org/10.1093/jnen/nly033.
Impact


Web of Science logo    citations in Web of Science

Scopus logo    citations in Scopus

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Spinal muscular atrophy (SMA) is characterized by the loss of α-motoneurons (MNs) with concomitant muscle denervation. MN excitability and vulnerability to disease are particularly regulated by cholinergic synaptic afferents (C-boutons), in which Sigma-1 receptor (Sig1R) is concentrated. Alterations in Sig1R have been associated with MN degeneration. Here, we investigated whether a chronic treatment with the Sig1R agonist PRE-084 was able to exert beneficial effects on SMA. We used a model of intermediate SMA, the Smn2B/− mouse, in which we performed a detailed characterization of the histopathological changes that occur throughout the disease. We report that Smn2B/− mice exhibited qualitative differences in major alterations found in mouse models of severe SMA: Smn2B/− animals showed more prominent MN degeneration, early motor axon alterations, marked changes in sensory neurons, and later MN deafferentation that correlated with conspicuous reactive gliosis and altered neuroinflammatory M1/M2 microglial balance. PRE-084 attenuated reactive gliosis, mitigated M1/M2 imbalance, and prevented MN deafferentation in Smn2B/− mice. These effects were also observed in a severe SMA model, the SMNΔ7 mouse. However, the prevention of gliosis and MN deafferentation promoted by PRE-084 were not accompanied by any improvements in clinical outcome or other major pathological changes found in SMA mice.
URI
http://hdl.handle.net/10459.1/67781
DOI
https://doi.org/10.1093/jnen/nly033
Is part of
Journal of Neuropathology and Experimental Neurology, 2018, vol. 77, num. 7, p. 577-597
European research projects
Collections
  • Articles publicats (Medicina Experimental) [323]
  • Articles publicats (IRBLleida) [1054]
  • Publicacions de projectes de recerca del Plan Nacional [2631]

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to 
 

 

Browse

All of the repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

View Usage Statistics

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to